Wednesday, June 10, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “modified”

433 pharma patents match "modified" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 433
Index total 30,257
Page 5 / 19

Quick answer

This filtered view shows 433 pharmaceutical patents matching "modified" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

433 results for “modified” · 30,257 patents in full index Clear search

  1. US 11230565

    Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry

    The Regents of the University of Colorado · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  2. US 11225648

    Modified DNase and uses thereof

    Protalix Ltd. · Granted Jan 18, 2022 · Expires Jan 13, 2042

    granted

  3. US 11219692

    Porphyrin modified telodendrimers

    The Regents of the University of California · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted

  4. CN 113874050

    MODIFIED CYANINE DYES AND CONJUGATES THEREOF

    BRACCO IMAGING SPA · Granted Dec 31, 2021 · Expires Dec 26, 2041

    granted

  5. US 11208655

    Functionally-modified oligonucleotides and subunits thereof

    Sarepta Therapeutics, Inc. · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted

  6. US 11203749

    Factor VII polypeptides that are modified and uses thereof

    Catalyst Biosciences, Inc. · Granted Dec 21, 2021 · Expires Dec 16, 2041

    granted

  7. US 11186822

    Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)

    Precision BioSciences, Inc. · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted

  8. US 11174292

    Substitutions-modified prefusion RSV F proteins and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted

  9. US 11166960

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Supernus Pharmaceuticals, Inc. · Granted Nov 9, 2021 · Expires Nov 4, 2041

    granted

  10. US 11161908

    BAFF-R targeted chimeric antigen receptor-modified t-cells and uses thereof

    The Board of Regents of the University of Texas System · Granted Nov 2, 2021 · Expires Oct 28, 2041

    granted

  11. US 11147837

    Modified cells and methods of therapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 19, 2021 · Expires Oct 14, 2041

    granted

  12. US 11135280

    Modified ebolavirus glycoproteins comprising mutations in the head and base domains that increase antibody cross-reactivity

    INTEGRATED BIOTHERAPEUTICS, INC. · Granted Oct 5, 2021 · Expires Sep 30, 2041

    granted

  13. US 11129794

    Chemically modified small molecules

    Nektar Therapeutics · Granted Sep 28, 2021 · Expires Sep 23, 2041

    granted

  14. US 11098283

    T cells modified to overexpress c-Myb

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 24, 2021 · Expires Aug 19, 2041

    granted

  15. US 11091555

    Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapy

    Five Prime Therapeutics, Inc. · Granted Aug 17, 2021 · Expires Aug 12, 2041

    granted

  16. US 11084844

    Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom

    Ionis Pharmaceuticals, Inc. · Granted Aug 10, 2021 · Expires Aug 5, 2041

    granted

  17. US 11078227

    5′-cyclo-phosphonate modified nucleotides

    Arrowhead Pharmaceuticals, Inc. · Granted Aug 3, 2021 · Expires Jul 29, 2041

    granted

  18. US 11078485

    Compositions comprising alternating 2′-modified nucleosides for use in gene modulation

    Ionis Pharmaceuticals, Inc. · Granted Aug 3, 2021 · Expires Jul 29, 2041

    granted

  19. US 11053484

    Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene

    Precision BioSciences, Inc. · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted

  20. US 11053290

    Modified Tamm-Horsfall protein and related compositions and methods of use

    The United States Government as Represented by the Department of Veterans Affair · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted

  21. US 11051499

    Genetically modified mice and engraftment

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted

  22. US 11008548

    Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)

    Precision BioSciences, Inc. · Granted May 18, 2021 · Expires May 13, 2041

    granted

  23. US 10993419

    Genetically modified cells, tissues, and organs for treating disease

    Regents of the University of Minnesota · Granted May 4, 2021 · Expires Apr 29, 2041

    granted

  24. US 10995156

    Acid-degradable and bioerodible modified polyhydroxylated materials

    The Regents of the University of California · Granted May 4, 2021 · Expires Apr 29, 2041

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.